From USFDA
Granules India announced that USFDA has approved the ANDA filed by USpharma Windlas, LLC through its subsidiaries, First Time US Generics LLC and Liberty Pharma, Inc. for Prasugrel Tablets 5 mg and 10 mg. The approved ANDA is the bioequivalent to the reference listed drug product, Effient Tablet 5mg and 10 mg of Eli Lilly and Company.Granules India through its wholly owned subsidiaries, Granules Pharmaceuticals Inc. had acquired the exclusive rights from USpharma Windlas, LLC in June 2016 to market and distribute its four products in USA, including Prasugrel.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app